Whether the ultimate goal is securing a partnership, selling your asset to a large biopharmaceutical company, or successfully navigating your way through the clinical drug development process on your way to achieving commercial success, this symposium is for you.
Since 2006, close to 10 percent of the new drug approvals granted by the FDA have been via the Accelerated Approval pathway. In 2015, the FDA granted a record 45 drug approvals, with 6 granted approved under the Accelerated Approval program. In 2015, EMA granted 39 authorizations, with 5, or 13 percent, under conditional authorization.
This symposium provides local biotechnology innovators direct access to industry leaders with experience in preparing companies for the scientific, logistical, regulatory and commercial challenges of taking a promising asset from lab to life.
Hosted by inVentiv Health, a global, top-tier professional services company that helps accelerate the clinical and commercial success of biopharmaceutical companies worldwide, this symposium features clinical drug development and commercial industry experts that are available to answer your questions and help you anticipate your needs.
